Smart drug strategy targets hidden cancer cells in young CLL patients

NCT ID NCT05478512

First seen Mar 26, 2026 · Last updated May 07, 2026 · Updated 8 times

Summary

This study tests a personalized treatment plan for young adults (18-65) with high-risk chronic lymphocytic leukemia (CLL) who have not had prior therapy. Patients first receive a combination of two drugs (venetoclax and obinutuzumab). Then, based on whether any cancer cells remain hidden, they either continue with one drug or switch to a different two-drug combo (venetoclax and zanubrutinib) to try to wipe out all traces of the disease. The goal is to tailor treatment to each person's response, potentially reducing long-term medication needs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ematologia AO di Perugia

    Perugia, Italy

  • Ematologia AOU Careggi

    Florence, Italy

  • Ematologia AOUS - Policlinico S. M. alle Scotte

    Siena, Italy

  • Ematologia IRST D.Amadori

    Meldola, Italy

  • Ematologia Ospedale Infermi

    Rimini, Italy

  • Ematologia Ospedale S.M. delle Croci

    Ravenna, Italy

  • Ematologia Policlinico Gemelli

    Roma, Italy

  • Ematologia Policlinico Umberto I

    Roma, Italy

Conditions

Explore the condition pages connected to this study.